Search Results 991-1000 of 17880 for Assay

  1. A Study To Assess The Effectiveness And Safety Of Pacritinib In Patients With VEXAS Syndrome (PAXIS) - Mayo Clinic

    Positive Quantiferon (or other interferon gamma release assay) during Screening. Note: patients with indeterminant Quantiferon results may enroll. Known ...

  2. Fabrice Lucien-Matteoni, Ph.D. - Mayo Clinic Faculty Profiles

    Lucien-Matteoni's lab uses advanced proteomic methodologies, functional assays and animal models to characterize the identity and function of the cancer ...

  3. A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer - Mayo Clinic

    ... assays proscribed in Section 13.6 (Correlative Studies) of this protocol may be conducted. Submission of the tissue does not have to occur prior to ...

  4. Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA - Mayo Clinic

    ... assay. Exclusion Criteria: Prior invasive malignancy (except node negative, non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 ...

  5. Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) - Mayo Clinic

    Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal. Recovery to Grade 1 or ...

  6. Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma - Mayo Clinic

    ... assays performed in clinical laboratory improvement amendments (CLIA)-approved laboratories ... assay. Exclusion Criteria: Definitive clinical or radiologic ...

  7. Clinical Trials - PR3-AAV Resilient Remission or PRRR

    - Positive serum assays for ANCA directed against myeloperoxidase (MPO-ANCA) - Non-severe AAV, defined as disease that does not justify treatment with both ...

  8. Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Measurable disease defined by any of following: Serum M-protein > 1 g/dL; Urine M-protein > 200 mg/24h; Serum free light chain (FLC) assay: involved FLC ...

  9. A Study to Evaluate the Effectiveness of Spesolimab to Treat Hidradenitis Suppurativa - Mayo Clinic

    Participation eligibility · Patients with active tuberculosis should be excluded; · Patients will be screened with Interferon Gamma Release Assay (IGRA) such as ...

  10. A Study Of GC012F (AZD0120), A CAR T Therapy Targeting CD19 And BCMA In Subjects With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    ... assay: involved FLC level is ≥10 mg/dL (100 mg/L) and serum kappa lambda FLC ratio is abnormal. * Adequate bone marrow and organ function assessment at ...